ReviewClinical & developmental immunology2013
Human monoclonal antibody-based therapy in the treatment of invasive candidiasis.
Review in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- Immunotherapy in Ocular Fungal Infections: Advances and Emerging Strategies.Current microbiology · 2026Review
- Phage Display-Derived Peptides Have Neutralizing Activities Against Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Anti-biofilm peptides can rescue fluconazole and amphotericin B efficacies against Candida albicans.Scientific reports · 2025Article
- Interplay between fungal infections and autoimmunity: mechanisms and therapeutic perspectives.EMBO molecular medicine · 2025Review
- Recent innovations and challenges in the treatment of fungal infections.Frontiers in cellular and infection microbiology · 2025Review
- Polymyxin-resistant hypervirulentFrontiers in microbiology · 2025Article
- Understanding the clinical and environmental drivers of antifungal resistance in the One Health context.Microbiology (Reading, England) · 2024Review
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Human-Fungal Pathogen Interactions from the Perspective of Immunoproteomics Analyses.International journal of molecular sciences · 2024Review
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- Sources of Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2023Review
- Immunotherapies against human bacterial and fungal infectious diseases: A review.Frontiers in medicine · 2023Review
- Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance.Frontiers in fungal biology · 2023Review
- Ssa1-targeted antibody prevents host invasion byFrontiers in microbiology · 2023Article
- Article
- A PreliminaryFrontiers in microbiology · 2022Article
- Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections.Frontiers in microbiology · 2022Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive candidiasis (IC) represents the leading fungal infection of humans causing life-threatening disease in immunosuppressed and neutropenic individuals including also the intensive care unit patients. Despite progress in recent years in drugs development for the treatment of IC, morbidity and mortality rates still remain very high. Historically, cell-mediated immunity and innate immunity are considered to be the most important lines of defense against candidiasis. Nevertheless recent evidence demonstrates that antibodies with defined specificities could act with different degrees showing protection against systemic and mucosal candidiasis. Mycograb is a human recombinant monoclonal antibody against heat shock protein 90 (Hsp90) that was revealed to have synergy when combined with fluconazole, caspofungin, and amphotericin B against a broad spectrum of Candida species. Furthermore, recent studies have established an important role for Hsp90 in mediating Candida resistance to echinocandins, giving to this antibody molecule even more attractive biological properties. In response to the failure of marketing authorization by the CHMP (Committee for Medicinal Products for Human Use) a new formulation of Mycograb, named Mycograb C28Y variant, with an amino acid substitution was developed in recent years. First data on Mycograb C28Y variant indicate that this monoclonal antibody lacked efficacy in a murine candidiasis model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.